Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Titel:
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Auteur:
Cortes, Javier Cescon, David W Rugo, Hope S Nowecki, Zbigniew Im, Seock-Ah Yusof, Mastura Md Gallardo, Carlos Lipatov, Oleg Barrios, Carlos H Holgado, Esther Iwata, Hiroji Masuda, Norikazu Otero, Marco Torregroza Gokmen, Erhan Loi, Sherene Guo, Zifang Zhao, Jing Aktan, Gursel Karantza, Vassiliki Schmid, Peter